A comprehensive review on the pancreatic lipase inhibitory peptides: A future anti-obesity strategy

Author:

Chia Tan Yong1ORCID,Gan Chee-Yuen1ORCID,Shafie Muhammad Hakimin1ORCID,Yap Pei Gee1ORCID,Mohd Rodhi Ainolsyakira1ORCID,Ahmad Ashfaq2ORCID,Murugaiyah Vikneswaran34ORCID,Abdulla Mohammed H5ORCID,Johns Edward James5ORCID

Affiliation:

1. Analytical Biochemistry Research Centre (ABrC), Universiti Innovation Incubator Building, SAINS@USM Campus, Universiti Sains Malaysia, Lebuh Bukit Jambul 11900, Penang, MALAYSIA

2. College of Pharmacy, University of Hafr Al Batin, Hafr Al Batin, SAUDI ARABIA

3. Department of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, MALAYSIA

4. Center for Drug Research, Universiti Sains Malaysia, Penang, MALAYSIA

5. Department of Physiology, School of Medicine, University College of Cork, Cork, IRELAND

Abstract

Dysregulation of lipid homeostasis contributes to obesity and can directly lead to several critical public health concerns globally. This paper aimed to present a brief review of related properties and the use of pancreatic lipase inhibitors as the future weight loss drug discovery and development procured from a wide range of natural sources. A total of 176 pancreatic lipase inhibitory peptides were identified from recent publications and peptide databases. These peptides were classified into three categories according to their peptide length and further analyzed using bioinformatic approaches to identify their structural activity relationship. Molecular docking analyses were conducted for each amino acid at the terminal position of the peptides to predict the binding affinity between peptide-enzyme protein complexes based on intermolecular contact interactions. Overall, the observations revealed the features of the inhibitory peptides and their inhibitory mechanisms and interactions. These findings strived to benefit scientists whose research may be relevant to anti-obesity drug development and/or discovery thereby support effective translation of preclinical research for humans’ health being.

Publisher

Modestum Ltd

Subject

General Medicine

Reference60 articles.

1. WHO. Overweight and obesity. World Health Organization; 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (Accessed: 1 December 2021).

2. Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: An endocrine society scientific statement. Endocr Rev. 2018;39(2):79-132. https://doi.org/10.1210/er.2017-00253 PMid:29518206 PMCid:PMC5888222

3. Liu T-T, Liu X-T, Chen Q-X, Shi Y. Lipase inhibitors for obesity: A review. Biomed Pharmacother. 2020;128:110314. https://doi.org/10.1016/j.biopha.2020.110314 PMid:32485574

4. Avila C, Holloway AC, Hahn MK, et al. An overview of links between obesity and mental health. Curr Obes Rep. 2015; 4(3):303-10. https://doi.org/10.1007/s13679-015-0164-9 PMid:26627487

5. NIDDK. Treatment for overweight & obesity. NIDDK; 2021. Available at: https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/treatment (Accessed: 4 December 2021).

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3